Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Goldman Sachs Group Inc acquired 500,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the insider directly owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Goldman Sachs Group Inc also recently made the following trade(s):
- On Wednesday, August 5th, Goldman Sachs Group Inc sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total value of $2,251,572.96.
- On Wednesday, August 5th, Goldman Sachs Group Inc bought 85,000 shares of Attovia Therapeutics stock. The shares were bought at an average price of $21.00 per share, for a total transaction of $1,785,000.00.
Attovia Therapeutics Trading Up 6.2%
Shares of ATTO traded up $1.12 during trading hours on Thursday, reaching $19.18. The company had a trading volume of 406,507 shares, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 12-month low of $16.15 and a 12-month high of $22.79.
Institutional Investors Weigh In On Attovia Therapeutics
About Attovia Therapeutics
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Further Reading
- Five stocks we like better than Attovia Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
